false
--12-31
0001321834
0001321834
2024-02-13
2024-02-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
Current
Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 13, 2024
MyMD
Pharmaceuticals, Inc
(Exact name of Registrant as specified in its charter)
| New
Jersey |
|
001-36268 |
|
22-2983783 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
No.) |
|
(IRS
Employer
Identification
No.) |
855
N. Wolfe Street, Suite 601
Baltimore, MD 21205
(Address of principal executive offices and zip code)
Registrant’s
telephone number, including area code: (856) 848-8698
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
Registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
stock, no par value per share |
|
MYMD |
|
The
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item
3.03 | Material
Modification to Rights of Security Holders. |
To
the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K (this “Current
Report”) is incorporated herein by reference.
| Item
5.03 | Amendment
to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
On
February 13, 2024, MyMD Pharmaceuticals, Inc. (the “Company”) announced that it had filed with the Secretary of State
of the State of New Jersey a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Charter
Amendment”) to effect a 1-for-30 reverse stock split (the “Reverse Stock Split”) of the Company’s
common stock, without par value (the “Common Stock”), effective as of 4:05 p.m. Eastern Standard Time on February
14, 2024 (the “Effective Time”). The Reverse Stock Split will decrease the number of shares of Common Stock issued
and outstanding from 62,749,125 shares to approximately 2,091,638 million shares, subject to adjustment for the rounding up of fractional
shares. The Reverse Stock Split will reduce the total number of issued and outstanding shares of Common Stock, including shares held
by the Company as treasury shares, by a ratio of 1-for-30. Accordingly, each holder of Common Stock will own fewer shares of Common Stock
as a result of the Reverse Stock Split. However, the Reverse Stock Split will affect all holders of Common Stock uniformly and will not
affect any stockholder’s percentage ownership interest in the Company, except to the extent that the Reverse Stock Split would
result in an adjustment to a stockholder’s ownership of Common Stock due to the treatment of fractional shares in the Reverse Stock
Split. Therefore, voting rights and other rights and preferences of the holders of Common Stock will not be affected by the Reverse Stock
Split (other than as a result of the treatment of fractional shares). Common stock issued pursuant to the Reverse Stock Split will remain
fully paid and nonassessable, without any change in the par value per share.
Simultaneously
with the Reverse Stock Split, the number of shares of Common Stock that
the Company shall have authority to issue will be reduced by a factor of 30 from 500 million (500,000,000) shares to sixteen million
six hundred and sixty-six thousand six hundred and sixty-six (16,666,666) shares.
A
copy of the Charter Amendment is attached as Exhibit 3.1 hereto and incorporated herein by reference.
No
fractional shares are being issued as a result of the Reverse Stock Split. Any fractional shares of outstanding shares of Common Stock
that would otherwise have resulted from the Reverse Stock Split will be rounded up to the nearest whole share of Common Stock.
The
Common Stock will begin trading on a Reverse Stock Split-adjusted basis on The Nasdaq Capital Market on February 15, 2024. The trading
symbol for the Common Stock will remain “MYMD.” The new CUSIP number for the Common Stock following the Reverse Stock Split
will be 62856X201.
Effects
of the Reverse Stock Split on Outstanding Warrants and Preferred Stock
Proportionate
adjustments will be made to the per share exercise price and the number of shares of Common Stock that may be purchased upon exercise
of outstanding warrants granted by the Company and the per share conversion price and the number of shares of Common Stock that may be
issued upon conversion of outstanding shares of convertible preferred stock issued by the Company.
In
addition, the Certificate of Designations (the “Certificate of Designations”) of the Company’s Series F Convertible
Preferred Stock, without par value (the “Series F Preferred Stock”) and the warrants issued concurrently with the
Series F Preferred Stock (the “February 2023 Warrants”) contain provisions that require the reduction of the conversion
price and exercise price of the Series F Preferred Stock and the February 2023 Warrants, respectively, as then in effect, on the sixteenth
(16th) trading day immediately following a reverse stock split if the “Event Market Price” is less than the conversion price
or exercise price then in effect. The term “Event Market Price” is used in the Certificate of Designations and the February
2023 Warrant to refer to, with respect to a reverse stock split, the quotient determined by dividing (x) the sum of the VWAP (as defined
in the Certificate of Designations and the February 2023 Warrant, respectively) of the Common Stock
for each of the five (5) lowest trading days
during the twenty (20) consecutive trading day period ending and including the trading day immediately preceding the sixteenth (16th)
trading day after such reverse stock split, divided by (y) five (5). The number of shares of Common Stock issuable upon exercise of the
February 2023 Warrants
will be increased in proportion to any such reduction, such that the aggregate exercise price of the February
2023 Warrants will remain the same following the
reduction.
Effects
of the Reverse Stock Split on Outstanding Equity Awards and Plans
Proportionate
adjustments will be made to the number of shares of Common Stock reserved for future issuance under the Company’s 2021 Equity Incentive
Plan (“2021 Plan”).
The
terms of equity awards granted under the 2013 Stock Incentive Plan, the 2016 Stock Incentive Plan, the 2017 Stock Incentive Plan, the
2018 Stock Incentive Plan, or 2021 Plan (collectively, the “Plans”), including (i) the number of shares and type of
Common Stock (or the securities or property) which thereafter may be made the subject of awards; (ii) the number of shares and type of
Common Stock (or other securities or property) subject to outstanding awards; (iii) the option price of each outstanding stock option
and (iv) the amount, if any, paid for forfeited shares in accordance with the terms of the Plans, will be proportionally adjusted to
the end that the same proportion of the Company’s issued and outstanding shares of Common Stock in each instance shall remain subject
to exercise at the same aggregate exercise price; provided, however, that the number of shares subject to an award granted under the
Plans shall be rounded down to the nearest whole share of Common Stock in order to comply with the requirements of Sections 409A and
424 of the Internal Revenue Code of 1986, as amended, and that the exercise price of any award shall be rounded up to the nearest whole
cent. In addition, the total number of shares of Common Stock that may be the subject of future grants under the Plans, as well as any
plan limits on the size of such grants will be adjusted and proportionately decreased as a result of the Reverse Stock Split.
Exchange
of Share Certificates
At
the Effective Time, each certificate representing pre-Reverse Stock Split shares of Common Stock will be deemed for all corporate purposes
to evidence ownership of post-Reverse Stock Split Common Stock. As soon as practicable after the Effective Time, the Company’s
transfer agent, Securities Transfer Corporation, will mail a letter of transmittal to the Company’s stockholders containing instructions
on how a stockholder should surrender its, his or her certificate(s) representing pre-Reverse Stock Split shares of Common Stock to the
Company’s transfer agent in exchange for certificate(s) representing post-Reverse Stock Split shares of Common Stock. No certificate(s)
representing post-Reverse Stock Split shares of Common Stock will be issued to a stockholder until such stockholder has surrendered all
certificate(s) representing pre-Reverse Stock Split shares of Common Stock, together with a properly completed and executed letter of
transmittal, to the Company’s transfer agent. No stockholder will be required to pay a transfer or other fee to exchange its, his
or her certificate(s) representing pre-Reverse Stock Split shares of Common Stock for certificate(s) representing post-Reverse Stock
Split shares of Common Stock registered in the same name.
Stockholders
who hold uncertificated shares of Common Stock electronically in “book-entry” form will have their holdings electronically
adjusted by the Company’s transfer agent (and, for beneficial owners, by their brokers or banks that hold in “street name”
for their benefit, as the case may be) to give effect to the Reverse Stock Split. If any certificate(s) or book-entry statement(s) representing
pre-Reverse Stock Split shares of Common Stock to be exchanged contain a restrictive legend or notation, as applicable, the certificate(s)
or book-entry statement(s) representing post-Reverse Stock Split shares of Common Stock will contain the same restrictive legend or notation.
Any
stockholder whose share certificate(s) representing pre-Reverse Stock Split shares of Common Stock has been lost, stolen or destroyed
will only be issued post-Reverse Stock Split Common Stock after complying with the requirements that the Company and the Company’s
transfer agent customarily apply in connection with lost, stolen or destroyed certificates.
STOCKHOLDERS
SHOULD NOT DESTROY STOCK CERTIFICATES REPRESENTING PRE-REVERSE STOCK SPLIT SHARES OF COMMON STOCK AND SHOULD NOT SUBMIT ANY STOCK CERTIFICATES
REPRESENTING PRE-REVERSE STOCK SPLIT SHARES OF COMMON STOCK UNTIL THEY ARE REQUESTED TO DO SO.
| Item
7.01 | Regulation
FD Disclosure. |
On
February 13, 2024, the Company issued a press release announcing the Reverse Stock Split. A copy of the press release is attached as
Exhibit 99.1 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached
hereto as Exhibit 99.1.
In
accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including
Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by
reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended
to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that
the dissemination of such information is required by Regulation FD.
| Item
9.01 | Financial
Statements and Exhibits. |
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
MYMD
PHARMACEUTICALS, INC. |
| |
|
|
| Date:
February 13, 2024 |
By:
|
/s/
Chris Chapman |
| |
|
Chris
Chapman, M.D. |
| |
|
President
and Chief Medical Officer |
Exhibit
3.1
New
Jersey Division of Revenue
CERTIFICATE
OF AMENDMENT
to the
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
(For Use by Domestic Profit Corporation)
Pursuant
to the provisions of Sections 14A:9-2(2), 14A:9-4(2), and 14A:7-15.1(3), Corporations, General, of the New
Jersey Statutes, the undersigned corporation executes the following Certificate of Amendment to its Amended and Restated Certificate
of Incorporation, dated February 5, 2024:
| 1. | The
name of the Corporation is: MyMD Pharmaceuticals, Inc. |
| 2. | The
following amendment to the Amended and Restated Certificate of Incorporation was approved
by the directors of the Corporation on January 22, 2024: |
Resolved
that each thirty (30) issued and outstanding shares
of the Corporation’s Common Stock, without par value, shall be combined into one (1) share of the Corporation’s Common Stock,
without par value, and that Article IV of the Amended and Restated Certificate of Incorporation
of the Corporation be amended by deleting Article IV in its entirety and substituting
the following in lieu thereof:
“The
total number of shares of stock which the Corporation shall have authority to issue is sixty-six million six hundred and sixty-six thousand
six hundred and sixty-six (66,666,666) shares, of which sixteen million six hundred and sixty-six thousand six hundred and sixty-six
(16,666,666) shares shall be common stock, without par value (“Common Stock”), and 50 million (50,000,000) shares shall be
preferred stock, without par value (“Preferred Stock”). Of the 50 million shares of Preferred Stock authorized by this Amended
and Restated Certificate of Incorporation, the Corporation previously approved and designated 1,990,000 shares as Series C Convertible
Preferred Stock, of which 1,990,000 shares remain designated as Series C Convertible Preferred Stock, 211,353 shares as Series D Convertible
Preferred Stock, of which 211,353 shares remain designated as Series D Convertible Preferred Stock, 100,000 shares as Series E Junior
Participating Preferred Stock, of which 100,000 shares remain designated as Series E Junior Participating Preferred Stock, and 15,000
shares as Series F Convertible Preferred Stock, of which 15,000 shares remain designated as Series F Convertible Preferred Stock, which
will remain in full force and effect after the filing of this Amended and Restated Certificate of Incorporation. The rights, preferences,
privileges and restrictions of such previously designated Preferred Stock are set forth in Annex A, B, and C respectively, hereto, and
in that certain Certificate of Designations of Series F Convertible Preferred Stock filed with the Secretary of State of the State of
New Jersey on March 16, 2023, all of which are incorporated herein by reference.
Simultaneously
with the effective time stated in this amendment (the “Effective Time”) and without regard to any other provision of these
Articles of Incorporation, each share of the Corporation’s Common Stock either issued or outstanding or held by the Corporation
as treasury stock immediately prior to the Effective Time (the “Old Common Stock”), will be automatically reclassified as
(without any further act) into a smaller number of shares such that each thirty (30) shares of Old Common Stock issued and outstanding
or held by the Corporation as treasury stock immediately prior to the Effective Time is combined into one (1) share of Common Stock (the
“New Common Stock”), without increasing or decreasing the amount of stated capital or paid-in surplus of the Corporation
(the “Reverse Stock Split”). The Board of Directors shall make provision for the issuance of that number of fractions of
New Common Stock such that any fractional share of a holder otherwise resulting from the Reverse Stock Split shall be rounded up to the
next whole number of shares of New Common Stock. Any stock certificate that, immediately prior to the Effective Time, represented shares
of the Old Common Stock will, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange,
represent the number of shares of the New Common Stock into which such shares of Old Common Stock shall have been reclassified plus the
fraction, if any, of a share of New Common Stock issued as aforesaid.”
| 3. | This
amendment provides for the combination of the Corporation’s shares of common stock,
as set forth under Item 2 above. |
| 4. | This
amendment will not adversely affect the rights or preferences of the holders of outstanding
shares of any class or series and will not result in the percentage of authorized shares
that remains unissued after the share combination exceeding the percentage of authorized
shares that was unissued before the share combination. |
| 5. | This
amendment shall be effective on February 14, 2024, at 4:05 p.m. Eastern Standard Time. |
[Signature
page follows.]
[Signature
page to Certificate of Amendment (Reverse Stock Split)]
IN
WITNESS WHEREOF, MyMD Pharmaceuticals, Inc. has caused
this Certificate to be duly executed by the undersigned duly authorized officer as of this 5th day of February, 2024.
| |
MyMD
Pharmaceuticals, Inc. |
| |
|
|
| |
By: |
/s/
Christopher Chapman, M.D. |
| |
Name: |
Christopher
Chapman, M.D. |
| |
Title:
|
President
and Chief Medical Officer |
Exhibit
99.1
MyMD
Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
Common
Stock Will Begin Trading on Split-Adjusted Basis on February 15, 2024
BALTIMORE,
MD – February 13, 2024 – MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”),
a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory
conditions, announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for
every 30 pre-split shares. The reverse stock split will become effective at 4:05 p.m. Eastern Standard Time on Wednesday, February 14,
2024. MyMD’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol MYMD and will begin trading
on a split-adjusted basis when the market opens on Thursday, February 15, 2024. The new CUSIP number for MyMD’s common stock following
the reverse stock split will be 62856X201.
At
the effective time of the reverse stock split, every 30 shares of MyMD’s issued and outstanding common stock will be converted
automatically into one issued and outstanding share of common stock without any change in the par value per share. Simultaneously therewith,
the number of shares of common stock that the Company shall have authority to issue will be reduced by a factor of 30 from 500,000,000
shares to 16,666,666 shares. Stockholders holding shares through a brokerage account will have their shares automatically adjusted to
reflect the 1-for-30 reverse stock split. It is not necessary for stockholders holding shares of the Company’s common stock in
certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse
stock split, although stockholders may do so if they wish.
The
reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s
equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. Any fractional share
of a stockholder resulting from the reverse stock split will be rounded up to the nearest whole number of shares. The reverse stock split
will reduce the number of shares of MyMD’s common stock outstanding from 62,749,125 shares
to approximately 2,091,638 shares, subject to adjustment for the rounding up of fractional shares.
Proportional adjustments will be made to the number of shares of MyMD’s common stock issuable upon exercise or conversion of MyMD’s
equity awards, convertible preferred stock and warrants, as well as the applicable exercise or conversion price. Stockholders with shares
in brokerage accounts should direct any questions concerning the reverse stock split to their broker; all other stockholders may direct
questions to the Company’s transfer agent, Securities Transfer Corporation, via email at issuerservices@stctransfer.com
or phone at (469) 633-0101.
About
MyMD Pharmaceuticals, Inc.
MyMD
Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on
developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1 is a drug
platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation,
and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune
diseases. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD
is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market,
which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit www.mymd.com.
Cautionary
Statement Regarding Forward-Looking Statements
This
press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties
and other factors which may cause actual results, performance or achievements to be materially different from any expected future results,
performance, or achievements. Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates
assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,”
“estimate,” “expect,” “may,” “plan,” “will,” “would’’ and
other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results
to differ materially from those indicated by such forward-looking statements include, without limitation: the effect that the reverse
stock split may have on the price of MyMD’s common stock; MyMD’s ability to regain and maintain compliance with the Nasdaq
Stock Market’s listing standards; the timing of, and MyMD’s ability to, obtain and maintain regulatory approvals for clinical
trials of MyMD’s pharmaceutical candidates; the timing and results of MyMD’s planned clinical trials for its pharmaceutical
candidates; the amount of funds MyMD requires for its pharmaceutical candidates; increased levels of competition; changes in political,
economic or regulatory conditions generally and in the markets in which MyMD operates; MyMD’s ability to retain and attract senior
management and other key employees; MyMD’s ability to quickly and effectively respond to new technological developments; MyMD’s
ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and
prevent others from infringing on MyMD’s proprietary rights; and the impact of the ongoing COVID-19 pandemic on MyMD’s results
of operations, business plan and the global economy. A discussion of these and other factors with respect to MyMD is set forth in the
Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed by MyMD on March 31, 2023. Forward-looking statements
speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
Investor
Contact:
Robert
Schatz
(646) 421-9523
rschatz@mymd.com
www.mymd.com
Media
Contact:
media@mymd.com
v3.24.0.1
Cover
|
Feb. 13, 2024 |
| Cover [Abstract] |
|
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
Feb. 13, 2024
|
| Current Fiscal Year End Date |
--12-31
|
| Entity File Number |
001-36268
|
| Entity Registrant Name |
MyMD
Pharmaceuticals, Inc
|
| Entity Central Index Key |
0001321834
|
| Entity Tax Identification Number |
22-2983783
|
| Entity Incorporation, State or Country Code |
NJ
|
| Entity Address, Address Line One |
855
N. Wolfe Street
|
| Entity Address, Address Line Two |
Suite 601
|
| Entity Address, City or Town |
Baltimore
|
| Entity Address, State or Province |
MD
|
| Entity Address, Postal Zip Code |
21205
|
| City Area Code |
(856)
|
| Local Phone Number |
848-8698
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common
stock, no par value per share
|
| Trading Symbol |
MYMD
|
| Security Exchange Name |
NASDAQ
|
| Entity Emerging Growth Company |
false
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
| Name: |
dei_CurrentFiscalYearEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:gMonthDayItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Apr 2023 to Apr 2024
